Batterjee Medical Services is a part of the AM Batterjee Group of companies, based in Jeddah, Saudi Arabia. This very well respected company is affiliated with the family owned chain of hospitals throughout the Middle East, a private medical University, and services and products throughout Saudi Arabia and the GCC. There are 386 Hospitals in Saudi Arabia serving a population of more than 23 million people.
There exists a well financed social healthcare environment. All Saudi Arabians receive healthcare insurance. With a total combined population of more than 80 million people in the gulf region, hundreds of hospitals and a need to modernize the medical product inventory, the AM Batterjee Group has committed to selling Oxyview® and OxyAlert® into a very modernized healthcare delivery system.
Chronic respiratory diseases represent a public health challenge in both industrialized and developing countries. According to recent studies performed in Saudi Arabia, COPD was found to be the second leading cause of hospitalizations (17.2%) among patients with respiratory disorders. Men are twice affected as women and the age group mostly involved is 46-65 years.
“Ingen Technologies is now starting to gain some momentum with its respiratory product line. We are very close to finalizing several other export possibilities in Asia, Australia, Europe and South America. We will make these announcements when the contracts are final,” stated Thomas Neavitt, CFO.
For more information please visit:
http://www.ingen-tech.com
http://www.batterjeemedical.com/products.htm
http://www.saudinf.com/main/h91.htm
http://www.thoracicmedicine.org
http://www.bmc.edu.sa/
http://www.ambatterjee.com/
http://www.batterjeemedical.com/
About Ingen Technologies, Inc.
Ingen is an emerging public company (ITEC:PK), registered and licensed by the FDA/DHS. The company introduced Oxyview® into the respiratory market in 2007; the world’s first in-line oxygen flow meter. The company has expanded its distribution in North America and Asia. Ingen has branded the Oxyview® with every major professional publication, and has gained the support from national recognized affiliates. The Company continues to adopt new OEM partners and expand the hospital based Group Purchasing Organizations as a part of the expansion program for distribution.
According to the 2002 CDC Report, there are approximately 32 million people living in the United States that suffer from Chronic Obstructive Pulmonary Disease, more commonly known as “COPD”. COPD is the major cause of hospitalizations and the fifth leading cause of death in the United States. A large portion of the COPD patients receive oxygen therapy. Ingen Technologies owns the patents and trademarks for Oxyview® and OxyAlert®, and there are no other products that compete or simulate either of these two products within the medical industry. For more information visit www.ingen-tech.com.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.
Contact: Ingen Technologies, Inc., Yucaipa Chris Wirth, 909-790-7180 info@ingen-tech.com
Source: Ingen Technologies, Inc.
